The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes

被引:16
|
作者
Lowey, Andrew [1 ]
Moore, Sara
Norris, Catherine
Wright, David
Silcock, Jonathan
Hammond, Peter
机构
[1] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Dept Pharm, Leeds LS9 7TF, W Yorkshire, England
[2] Harrogate & Dist Fdn Trust, Dept Pharm, Harrogate, England
[3] Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England
[4] Univ Leeds, Pharm Practice & Med Management Grp, Leeds LS2 9JT, W Yorkshire, England
来源
PHARMACY WORLD & SCIENCE | 2007年 / 29卷 / 05期
关键词
diabetes mellitus; hypertension; hyperlipidaemia; pharmacy; cost-effectiveness; cardiovascular risk; United Kingdom; pharmacoeconomics; pharmacist;
D O I
10.1007/s11096-007-9101-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
People with type 2 diabetes mellitus have an increased risk of cardiovascular and cerebrovascular disease compared with the general population. Following attempts to change lifestyle, pharmacological treatment is necessary to modify this risk. However, the use of medicines may be sub-optimal because of infrequent or inadequate medication review. Harrogate District Hospital, a medium-sized district general hospital in a rural area of North Yorkshire, England. A pharmacist-led hospital clinic was established to manage diabetic patients suffering from resistant hypertension with or without hyperlipidaemia. Patients with two consecutive elevated blood pressure (BP) readings (> 140/80 mmHg) were recruited via referral from out-patient clinics and diabetic nurse specialists. A range of clinical indicators were assessed on referral. The pharmacist prepared individualised patient information and a patient-held record card. An evidence-based algorithm was used to make adjustments (every 4 weeks) to anti-hypertensive medication. If necessary treatment of hyperlipidaemia was also optimised. Published data was used to predict the 10-year risk of coronary heart disease and cerebrovascular accident for each patient before and after intensive medicines management. Patients were discharged from the clinic after two consecutive target BP measurements. It is estimated that these risks were reduced by 11.9 and 9.6%, respectively, at a cost per event avoided of 34,708 pound and 63,320 pound. Intensive pharmacist-led clinics are potentially a cost-effective way to improve the cardiovascular health of patients with type 2 diabetes.
引用
收藏
页码:541 / 545
页数:5
相关论文
共 50 条
  • [1] The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes
    Andrew Lowey
    Sara Moore
    Catherine Norris
    David Wright
    Jonathan Silcock
    Peter Hammond
    [J]. Pharmacy World & Science, 2007, 29 : 541 - 545
  • [2] LONG-TERM COST-EFFECTIVENESS OF A PHARMACIST-LED MEDICATION THERAPY MANAGEMENT CLINIC (MTMC) FOR TYPE 2 DIABETES MANAGEMENT
    Joshi, M.
    Pham, C. M.
    Deng, H.
    Norton, R. M.
    Mathew, S.
    Tilton, J. J.
    Touchette, D. R.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [3] EFFECTIVENESS OF A PHARMACIST-LED MEDICATIONS MANAGEMENT SERVICE FOR ADULTS WITH TYPE 2 DIABETES MELLITUS
    Cheen, H. H. M.
    Martin, A. J.
    Lim, P. S.
    Chen, L. L.
    Lim, S. H.
    Chow, M. M. Y.
    Lim, J. C.
    Khee, G. Y.
    Wee, H. L.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S95 - S95
  • [4] Cost-effectiveness of treatment of type 2 diabetes
    Eastman, RC
    [J]. DIABETES CARE, 1998, 21 (03) : 464 - 465
  • [5] Pharmacist-Led Shared Medical Appointments for Multiple Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
    Cohen, Lisa B.
    Taveira, Tracey H.
    Khatana, Sameed Ahmed M.
    Dooley, Andrea G.
    Pirraglia, Paul A.
    Wu, Wen-Chih
    [J]. DIABETES EDUCATOR, 2011, 37 (06): : 801 - 812
  • [6] Cost-Effectiveness of Pharmacist-Led Deprescribing of NSAIDs in Community-Dwelling Older Adults
    Sanyal, Chiranjeev
    Turner, Justin P.
    Martin, Philippe
    Tannenbaum, Cara
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 68 (05) : 1090 - 1097
  • [7] Cost-Effectiveness of a Community Pharmacist-Led Sleep Apnea Screening Program - A Markov Model
    Perraudin, Clemence
    Le Vaillant, Marc
    Pelletier-Fleury, Nathalie
    [J]. PLOS ONE, 2013, 8 (06):
  • [8] Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management
    Schultz, Bob G.
    Tilton, Jessica
    Jun, Julie
    Scott-Horton, Tiffany
    Quach, Danny
    Touchette, Daniel R.
    [J]. VALUE IN HEALTH, 2021, 24 (04) : 522 - 529
  • [9] COST-EFFECTIVENESS OF ADDING A PHARMACIST TO THE PRIMARY CARE TEAM FOR THE MANAGEMENT OF TYPE 2 DIABETES PATIENTS
    Yu, J.
    Shah, B.
    Ip, E. J.
    Chan, J.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A181 - A181
  • [10] COST-EFFECTIVENESS ANALYSIS OF A PHARMACIST-LED INTERVENTION ON IMPROVING INHALER ADHERENCE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    van Boven, J. F.
    Tommelein, E.
    Boussely, K.
    Mehuys, E.
    Vegter, S.
    Blusselle, G. G.
    Rutten-van Molken, M. P. M. H.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A136 - A136